Assessment of peripheral biomarkers potentially involved in episodic and chronic migraine: a case-control study with a focus on NGF, BDNF, VEGF, and PGE2

Mohammad Mozafarihashjin, Mansoureh Togha, Zeinab Ghorbani, Abolfazl Farbod, Pegah Rafiee, Fahimeh Martami, Mohammad Mozafarihashjin, Mansoureh Togha, Zeinab Ghorbani, Abolfazl Farbod, Pegah Rafiee, Fahimeh Martami

Abstract

Background: Several inflammatory and vascular molecules, and neurotrophins have been suggested to have a possible role in the development of migraine. However, pathophysiological events leading to migraine onset and transformation of episodic migraine (EM) to chronic migraine (CM) are not fully understood. Thus, we aimed to assess peripheral levels of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), and prostaglandin E2 (PGE2) in EM and CM patients, and controls.

Methods: From September 2017 to June 2020, 89 subjects were enrolled in a case-control study; 23 and 36 EM and CM patients, respectively, and 30 age and sex-matched controls. Demographic data and medical history were obtained from all patients. Headache characteristics were recorded at baseline visit and ensuing 30 days for persons with migraine disease. Serum levels of NGF, BDNF, VEGF, and PGE2 were measured once for controls and EM and CM patients, and adjusted for age, sex, and body mass index.

Results: Serum levels of NGF were significantly lower in EM patients compared to controls and CM patients (P-value=0.003 and 0.042, respectively). Serum levels of BDNF were significantly lower in EM and CM patients as opposed to controls (P-value<0.001), but comparable between EM and CM patients (P-value=0.715). Peripheral blood levels of VEGF were significantly higher in EM and CM patients as opposed to controls (P-value<0.001), but not different between EM and CM patients (P-value=0.859). Serum levels of PGE2 were significantly lower in EM patients compared to controls (P-value=0.011), however similar between EM and CM patients (P-value=0.086). In migraine patients, serum levels of NGF and PGE2 positively correlated with headache frequency (NGF: ρ = 0.476 and P-value<0.001; PGE2: ρ = 0.286 and P-value=0.028), while corresponding levels of BDNF and VEGF did not correlate with headache frequency (BDNF: ρ = 0.037 and P-value=0.778; VEGF: ρ= -0.025 and P-value=0.850).

Conclusions: Our findings suggest that NGF, BDNF, PGE2, and VEGF may play a significant role in migraine pathogenesis and/or chronification, and therefore might bear potential value for novel targeted abortive and prophylactic migraine therapy. Further prospective cohort studies with larger sample sizes can more robustly evaluate the implications of these findings.

Keywords: Biomarker; Brain-derived neurotrophic factor; Headache; Migraine; Nerve growth factor; Prostaglandin E2; Vascular endothelial growth factor.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Serum levels of NGF, BDNF, VEGF and PGE2 in EM and CM patients, and controls. A NGF (B) BDNF (C) VEGF (D) PGE2; NGF: nerve growth factor; BDNF: brain-derived neurotrophic factor (BDNF); VEGF: vascular endothelial growth factor; PGE2: prostaglandin E2; EM: episodic migraine; CM: chronic migraine
Fig. 2
Fig. 2
Correlation between headache frequency and Serum levels of NGF, BDNF, VEGF and PGE2. A NGF (B) BDNF (C) VEGF (D) PGE2; NGF: nerve growth factor; BDNF: brain-derived neurotrophic factor (BDNF); VEGF: vascular endothelial growth factor; PGE2: prostaglandin E2

References

    1. Agosti R. Migraine Burden of Disease: From the Patient’s Experience to a Socio-Economic View. Headache: The Journal of Head and Face Pain. 2018;58:17–32. doi: 10.1111/head.13301.
    1. Leonardi M, Raggi A. A narrative review on the burden of migraine: when the burden is the impact on people’s life. J Headache Pain. 2019;20:41. doi: 10.1186/s10194-019-0993-0.
    1. Steiner TJ, Stovner LJ, Vos T, et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19:17. doi: 10.1186/s10194-018-0846-2.
    1. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.Lancet Neurol17:954–976. 10.1016/s1474-4422(18)30322-3
    1. Steiner TJ, Stovner LJ, Jensen R, et al. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21:137. doi: 10.1186/s10194-020-01208-0.
    1. Ghorbani Z, Rafiee P, Haghighi S, et al. The effects of vitamin D3 supplementation on TGF-β and IL-17 serum levels in migraineurs: post hoc analysis of a randomized clinical trial. Journal of Pharmaceutical Health Care and Sciences. 2021;7:9. doi: 10.1186/s40780-021-00192-0.
    1. Ashina M, Terwindt GM, Al-Karagholi MA-M, et al. Migraine: disease characterisation, biomarkers, and precision medicine. The Lancet. 2021;397:1496–1504. doi: 10.1016/S0140-6736(20)32162-0.
    1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1–211. 10.1177/0333102417738202
    1. Ashina M. Migraine. N Engl J Med. 2020;383:1866–1876. doi: 10.1056/NEJMra1915327.
    1. Dodick DW. A Phase-by-Phase Review of Migraine Pathophysiology. Headache: The Journal of Head and Face Pain. 2018;58:4–16. doi: 10.1111/head.13300.
    1. Togha M, Razeghi Jahromi S, Ghorbani Z, et al. An investigation of oxidant/antioxidant balance in patients with migraine: a case-control study. BMC Neurol. 2019;19:323. doi: 10.1186/s12883-019-1555-4.
    1. Togha M, Jahromi SR, Ghorbani Z et al (2020) Evaluation of Inflammatory State in Migraineurs: A Case-control Study. Iranian Journal of Allergy, Asthma and Immunology 19. 10.18502/ijaai.v19i(s1.r1).2864
    1. Antonova M, Wienecke T, Olesen J, Ashina M. Prostaglandins in migraine: update. Curr Opin Neurol. 2013;26:269–275. doi: 10.1097/WCO.0b013e328360864b.
    1. Ghorbani Z, Togha M, Rafiee P, et al. Vitamin D in migraine headache: a comprehensive review on literature. Neurol Sci. 2019;40:2459–2477. doi: 10.1007/s10072-019-04021-z.
    1. Zhang H, Zhang X, Zong D, et al. miR-34a-5p up-regulates the IL-1β/COX2/PGE2 inflammation pathway and induces the release of CGRP via inhibition of SIRT1 in rat trigeminal ganglion neurons. FEBS Open Bio. 2021;11:300–311. doi: 10.1002/2211-5463.13027.
    1. Jacobs B, Dussor G. Neurovascular contributions to migraine: Moving beyond vasodilation. Neuroscience. 2016;338:130–144. doi: 10.1016/j.neuroscience.2016.06.012.
    1. Michalak S, Kalinowska-Lyszczarz A, Wegrzyn D, et al. The Levels of Circulating Proangiogenic Factors in Migraineurs. Neuromol Med. 2017;19:510–517. doi: 10.1007/s12017-017-8465-7.
    1. Martins LB, Duarte H, Ferreira AVM, et al. Migraine is associated with altered levels of neurotrophins. Neurosci Lett. 2015;587:6–10. doi: 10.1016/j.neulet.2014.12.022.
    1. Oterino A, Toriello M, Valle N, et al. The Relationship Between Homocysteine and Genes of Folate-Related Enzymes in Migraine Patients. Headache: The Journal of Head and Face Pain. 2010;50:99–168. doi: 10.1111/j.1526-4610.2009.01484.x.
    1. Mottaghi T, Khorvash F, Askari G, et al. The relationship between serum levels of vitamin D and migraine. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences. 2013;18:S66–S70.
    1. Ghorbani Z, Togha M, Rafiee P, et al. Vitamin D3 might improve headache characteristics and protect against inflammation in migraine: a randomized clinical trial. Neurol Sci. 2020;41:1183–1192. doi: 10.1007/s10072-019-04220-8.
    1. Ghorbani Z, Rafiee P, Fotouhi A, et al. The effects of vitamin D supplementation on interictal serum levels of calcitonin gene-related peptide (CGRP) in episodic migraine patients: post hoc analysis of a randomized double-blind placebo-controlled trial. J Headache Pain. 2020;21:22. doi: 10.1186/s10194-020-01090-w.
    1. Burstein R, Noseda R, Borsook D. Migraine: Multiple Processes, Complex Pathophysiology. The Journal of Neuroscience. 2015;35:6619. doi: 10.1523/JNEUROSCI.0373-15.2015.
    1. Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012;78:1337. doi: 10.1212/WNL.0b013e3182535d20.
    1. Hepp Z, Bloudek LM, Varon SF. Systematic Review of Migraine Prophylaxis Adherence and Persistence. Journal of Managed Care Pharmacy. 2014;20:22–33. doi: 10.18553/jmcp.2014.20.1.22.
    1. Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS-II) Headache: The Journal of Head and Face Pain. 2013;53:644–655. doi: 10.1111/head.12055.
    1. Razeghi Jahromi S, Abolhasani M, Ghorbani Z, et al. Bariatric Surgery Promising in Migraine Control: a Controlled Trial on Weight Loss and Its Effect on Migraine Headache. Obes Surg. 2018;28:87–96. doi: 10.1007/s11695-017-2793-4.
    1. Guidance Document (2021) : Bioanalytical Method Validation Guidance for Industry. FDA. MAY 2018. Accessed October 7,
    1. Stuginski-Barbosa J, Dach F, Bigal M, Speciali JG. Chronic Pain and Depression in the Quality of Life of Women With Migraine – A Controlled Study. Headache: The Journal of Head and Face Pain. 2012;52:400–408. doi: 10.1111/j.1526-4610.2012.02095.x.
    1. Bottai M, Cai B, McKeown RE. Logistic quantile regression for bounded outcomes. Stat Med. 2010;29:309–317. doi: 10.1002/sim.3781.
    1. Cirulli F, Alleva E. The NGF saga: From animal models of psychosocial stress to stress-related psychopathology. Front Neuroendocr. 2009;30:379–395. doi: 10.1016/j.yfrne.2009.05.002.
    1. Shu X-Q, Mendell LM (1999) Neurotrophins and hyperalgesia. Proceedings of the National Academy of Sciences 96:7693. 10.1073/pnas.96.14.7693
    1. Yeh Y-W, Kuo S-C, Chen C-Y, et al. Harm avoidance involved in mediating the association between nerve growth factor (NGF) gene polymorphisms and antidepressant efficacy in patients with major depressive disorder. J Affect Disord. 2015;183:187–194. doi: 10.1016/j.jad.2015.05.012.
    1. Shimizu T, Shibata M, Suzuki N. Migraine: Advances in the pathophysiology and treatment. Rinsho Shinkeigaku. 2011;51:103–109. doi: 10.5692/clinicalneurol.51.103.
    1. Sarchielli P, Mancini ML, Floridi A, et al. Increased Levels of Neurotrophins Are Not Specific for Chronic Migraine: Evidence From Primary Fibromyalgia Syndrome. The Journal of Pain. 2007;8:737–745. doi: 10.1016/j.jpain.2007.05.002.
    1. Blandini F, Rinaldi L, Tassorelli C, et al. Peripheral Levels of BDNF and NGF in Primary Headaches. Cephalalgia. 2006;26:136–142. doi: 10.1111/j.1468-2982.2005.01006.x.
    1. Jang M-U, Park J-W, Kho H-S, et al. Plasma and saliva levels of nerve growth factor and neuropeptides in chronic migraine patients. Oral Dis. 2011;17:187–193. doi: 10.1111/j.1601-0825.2010.01717.x.
    1. Sarchielli P, Alberti A, Floridi A, Gallai V. Levels of nerve growth factor in cerebrospinal fluid of chronic daily headache patients. Neurology. 2001;57:132. doi: 10.1212/WNL.57.1.132.
    1. Sarchielli P, Alberti A, Gallai B, et al. Brain-derived neurotrophic factor in cerebrospinal fluid of patients with chronic daily headache: relationship with nerve growth factor and glutamate levels. J Headache Pain. 2002;3:129–135. doi: 10.1007/s101940200030.
    1. LIPSKY RH, MARINI ANNM. Brain-Derived Neurotrophic Factor in Neuronal Survival and Behavior-Related Plasticity. Ann N Y Acad Sci. 2007;1122:130–143. doi: 10.1196/annals.1403.009.
    1. Thompson SWN, Bennett DLH, Kerr BJ et al (1999) Brain-derived neurotrophic factor is an endogenous modulator of nociceptive responses in the spinal cord. Proceedings of the National Academy of Sciences 96:7714. 10.1073/pnas.96.14.7714
    1. Tanure MTA, Gomez RS, Hurtado RCL, et al. Increased serum levels of brain-derived neurotropic factor during migraine attacks: a pilot study. J Headache Pain. 2010;11:427–430. doi: 10.1007/s10194-010-0233-0.
    1. Sordyl J, Małecka-Tendera E, Sarecka-Hujar B, Kopyta I. Headache in Children: Selected Factors of Vascular Changes Involved in Underlying Processes of Idiopathic Headaches. Children (Basel, Switzerland) 2020;7:167. doi: 10.3390/children7100167.
    1. Lemos C, Mendonça D, Pereira-Monteiro J, et al. BDNF and CGRP interaction: Implications in migraine susceptibility. Cephalalgia. 2010;30:1375–1382. doi: 10.1177/0333102410368443.
    1. Fischer M, Wille G, Klien S, et al. Brain-derived neurotrophic factor in primary headaches. J Headache Pain. 2012;13:469–475. doi: 10.1007/s10194-012-0454-5.
    1. Mondal AC, Fatima M. Direct and indirect evidences of BDNF and NGF as key modulators in depression: role of antidepressants treatment. Int J Neurosci. 2019;129:283–296. doi: 10.1080/00207454.2018.1527328.
    1. Llorián-Salvador M, González-Rodríguez S. Painful Understanding of VEGF. Front Pharmacol. 2018;9:1267. doi: 10.3389/fphar.2018.01267.
    1. Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–676. doi: 10.1038/nm0603-669.
    1. Reinders MEJ, Sho M, Izawa A, et al. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Investig. 2003;112:1655–1665. doi: 10.1172/JCI17712.
    1. Rodríguez-Osorio X, Sobrino T, Brea D, et al. Endothelial progenitor cells. Neurology. 2012;79:474. doi: 10.1212/WNL.0b013e31826170ce.
    1. Takebayashi M, Hashimoto R, Hisaoka K, et al. Plasma levels of vascular endothelial growth factor and fibroblast growth factor 2 in patients with major depressive disorders. J Neural Transm. 2010;117:1119–1122. doi: 10.1007/s00702-010-0452-1.
    1. Loulergue P, Mir O, Rocheteau P, et al. Sertraline-induced increase in VEGF brain levels and its activity in cryptococcal meningitis. Lancet Infect Dis. 2016;16:891. doi: 10.1016/S1473-3099(16)30147-5.
    1. MacClellan LR, Giles W, Cole J, et al. Probable Migraine With Visual Aura and Risk of Ischemic Stroke. Stroke. 2007;38:2438–2445. doi: 10.1161/STROKEAHA.107.488395.
    1. Kurth T, Gaziano JM, Cook NR, et al. Migraine and Risk of Cardiovascular Disease in Men. Arch Intern Med. 2007;167:795–801. doi: 10.1001/archinte.167.8.795.
    1. Moriyama T, Higashi T, Togashi K, et al. Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol Pain. 2005;1:3. doi: 10.1186/1744-8069-1-3.
    1. Wienecke T, Olesen J, Oturai PS, Ashina M. Prostaglandin E2 (PGE2) Induces Headache in Healthy Subjects. Cephalalgia. 2009;29:509–519. doi: 10.1111/j.1468-2982.2008.01748.x.
    1. Wienecke T, Olesen J, Oturai PS, Ashina M (2008) Prostacyclin (epoprostenol) induces headache in healthy subjects.PAIN139
    1. Antonova M, Wienecke T, Olesen J, Ashina M. Pro-inflammatory and vasoconstricting prostanoid PGF2α causes no headache in man. Cephalalgia. 2011;31:1532–1541. doi: 10.1177/0333102411423314.
    1. Sarchielli P, Alberti A, Codini M, et al. Nitric Oxide Metabolites, Prostaglandins and Trigeminal Vasoactive Peptides in Internal Jugular Vein Blood During Spontaneous Migraine Attacks. Cephalalgia. 2000;20:907–918. doi: 10.1046/j.1468-2982.2000.00146.x.
    1. Mohammadian P, Hummel T, Arora C, Carpenter T. Peripheral Levels of Inflammatory Mediators in Migraineurs During Headache-free Periods. Headache: The Journal of Head and Face Pain. 2001;41:867–872. doi: 10.1111/j.1526-4610.2001.01158.x.
    1. Tuca JO, Planas JM, Parellada RP (1989) Increase in PGE2 and TXA2 in the Saliva of Common Migraine Patients. Action of Calcium Channel Blockers. Headache: The Journal of Head and Face Pain 29:498–501. 10.1111/j.1526-4610.1989.hed2908498.x
    1. Li C, Zhu Q, He Q, et al. Plasma Levels of Cyclooxygenase-2 (COX-2) and Visfatin During Different Stages and Different Subtypes of Migraine Headaches. Medical science monitor: international medical journal of experimental and clinical research. 2017;23:24–28. doi: 10.12659/msm.899269.
    1. Martami F, Razeghi Jahromi S, Togha M, et al. The serum level of inflammatory markers in chronic and episodic migraine: a case-control study. Neurol Sci. 2018;39:1741–1749. doi: 10.1007/s10072-018-3493-0.
    1. Torres-Ferrús M, Ursitti F, Alpuente A, et al. From transformation to chronification of migraine: pathophysiological and clinical aspects. J Headache Pain. 2020;21:42. doi: 10.1186/s10194-020-01111-8.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa